Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1

Current HIV Research

Volumn 8, Issue 3, 2010, Pages 194-198

  Taiwo, Babafemi ^a   Chaplin, Beth ^b   Penugonda, Sudhir ^a   Meloni, Seema ^b   Akanmu, Sulaimon ^c   Gashau, Wadzani ^d   Idoko, John ^e   Adewole, Isaac ^f   Murphy, Robert ^a   Kanki, Phyllis ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^d UNIVERSITY OF MAIDUGURI   (Nigeria)

^e UNIVERSITY OF JOS   (Nigeria)

^f UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Etravirine; Non B subtype; Resistance; Resource limited setting; Second line

Indexed keywords

ETRAVIRINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDAZINE DERIVATIVE; VIRUS PROTEIN;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CD4 LYMPHOCYTE COUNT; CLASSIFICATION ALGORITHM; COHORT ANALYSIS; DRUG ACTIVITY; DRUG EXPOSURE; DRUG RESISTANCE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATION; PRACTICE GUIDELINE; RISK FACTOR; VIRUS LOAD; ANTIVIRAL RESISTANCE; CLASSIFICATION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METHODOLOGY; TREATMENT FAILURE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEVIRAPINE; PYRIDAZINES; TREATMENT FAILURE; VIRAL LOAD; VIRAL PROTEINS;

EID: 77954041833     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210791111098     Document Type: Article

References (23)

1. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79(20): 12773-82.
2. Vingerhoets J, Buelens A, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC-125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther 2007; 12: S34.
3. Vingerhoets J, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther 2008; 13(Suppl 3): A26.
4. Jonhson VA, Brun-Vezinet F, Clotet B et al. Update on the drug resistance mutations in HIV-1. Topics HIV Med 2008; 16(5): 138-45.
5. Benhamida J, Chappey C, Coakley E, Parkin NT. HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weghting factors identified through correlation to phenotype. Antivir Ther 2008; 13(Suppl 3): A142.
6. Poveda E, de Mendoza C, Pattery T, González Mdel M, Villacian J, Soriano V. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 2008; 22(17): 2395-8.
7. Hirsch M, Günthard H, Schapiro J, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266-85.
8. UNAIDS 2008 Report on the global AIDS epidemic. Available at http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/. Accessed on January 19, 2009.
9. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr HIV Res 2008; 6(5): 474-6.
10. Scott C, Grover D, Nelson M. Is there a role for etravirine in patients with nonnucleoside reverse transcriptase inhibitor resistance? AIDS 2008; 22: 989-92.
11. Poveda E, Garrido C, de Mendoza C, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 60: 1411-3.
12. Llibre J, Santos J, Puig T, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 2008; 62(5): 909-13.
13. Picchio G, Vingerhoets J, Staes M, et al. Prevalence of TMC125 resistance-associated mutations in a large panel of clinical isolates. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008; Boston, MA, USA. Abstract 866.
14. Das K, Clark AD, Lewi PJ Jr, et al. Roles of conformational and positional adaptability in structure-based design of TMC125- R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-60.
15. Gonzales MJ, Wu TD, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17: 791Y 799.
16. iang S, Xing H, Si X, Wang Y, Shao Y. Polymorphism of the protease and reverse transcriptase and drug resistance mutation patterns of HIV-1 subtype B prevailing in China. J Acquir Immune Defic Syndr 2006; 42(4): 512-4.
17. Ceccherini-Silberstein F, Svicher V, Sing T, et al. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 2007; 81(20): 11507-19.
18. Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitorexperienced patients: study TMC125-C227. HIV Med 2008; 9(10): 883-96.
19. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 2008; 5(7): e158.
20. Paredes R, Lalama C, Ribaudo H, et al. Presence of minor populations of Y181C mutants detected by allele-specific PCR (ASPCR) and risk of efavirenz failure in treatment-naive patients: results of an ACTG A5095 case-cohort study. Abstract 83. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections. February 3-6, 2008; Boston, Massachusetts.
21. Lapadula G, Calabresi A, Castelnuovo F, et al. Prevalence and risk factors for etravirine resistance among patients failing on nonnucleoside reverse transcriptase inhibitors. Antivir Ther 2008; 13(4): 601-5.
22. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300(5): 555-70.
23. WHO. Antiretroviral therapy for HIV infection in adults and adolescents recommendations for a public health approach (2006 revision). Available at http://www.who.int/hiv/pub/guidelines/adult/en/index.html. Accessed July 21, 2009.